All In Biotech

NDA 202813 · Teva Branded Pharm

Qnasl

Beclomethasone Dipropionate · Nasal

Orphan

Last checked: Nov 20, 2026Latest source record: Mar 30, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Mar 23, 2012

Approved uses

3

Original approval plus efficacy supplements

Registered trials

196

79 Phase 3, 14 recruiting

FAERS reports

7,437

5,923 serious, 558 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 29, 2020.

1. INDICATIONS AND USAGE QNASL Nasal Aerosol is a corticosteroid indicated for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in patients 4 years of age and older. ( 1.1 ) 1.1 Treatment of Nasal Symptoms of Allergic Rhinitis QNASL ® Nasal Aerosol is indicated for the treatment of the nasal symptoms associated with seasonal and perennial allergic rhinitis in patients 4 years of age and older.

Mechanism: Beclomethasone dipropionate is a prodrug that is extensively converted to the active metabolite, beclomethasone-17-monopropionate. The precise mechanism through which beclomethasone dipropionate affects rhinitis symptoms is unknown. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and the release of inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines). Beclomethasone-17-monopropionate has been shown in vitro to...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • QNASL · BECLOMETHASONE DIPROPIONATE 0.04MG/ACTUATION · AEROSOL, METERED, NASAL · Prescription
  • QNASL · BECLOMETHASONE DIPROPIONATE 0.08MG/ACTUATION · AEROSOL, METERED, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Beclomethasone Dipropionate" as an intervention, any sponsor and status, largest first.

All 196 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea557
  • asthma369
  • headache354
  • vomiting349
  • nausea344
  • drug ineffective338
  • fatigue337
  • malaise318
  • diarrhoea314
  • cough306
  • pneumonia298
  • off label use251

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004206
2005233
2006167
2007230
2008278
2009151
2010146
2011221
2012399
2013273
2014207
2015234
2016291
2017158
2018182
2019217
2020236
2021319
2022690
2023691
2024743
2025725
2026440

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Qnasl (Beclomethasone Dipropionate)

2024 spending

$4.5M

Beneficiaries

2,924

10,598 claims

Per beneficiary

$1,548

$27.66 per unit

View as table
YearSpending
2020$5,582,361
2021$5,278,644
2022$5,082,343
2023$4,777,407
2024$4,527,468

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 907 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.